BioAge Labs, Inc.
BioAge Labs, Inc. (Nasdaq: BGEL) is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for metabolic diseases by targeting the biology of human aging. The company's approach leverages proprietary longitudinal human datasets spanning over 50 years of follow-up data, encompassing… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BioAge Labs, Inc. does
In the company’s own words
BioAge Labs, Inc. (Nasdaq: BGEL) is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for metabolic diseases by targeting the biology of human aging. The company's approach leverages proprietary longitudinal human datasets spanning over 50 years of follow-up data, encompassing more than 150 million molecular data points across 25,000 individual participant profiles. This unique resource enables BioAge to identify promising drug targets based on insights into molecular changes that drive aging and disease progression.
The company's lead program, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inflammasome inhibitor with a distinct mechanism and binding site from other NLRP3 inhibitors in development. BGE-102 has demonstrated robust target engagement and favorable pharmacokinetic properties in Phase 1 clinical trials. The company intends to advance BGE-102 in two therapeutic areas: cardiometabolic disease, with initial focus on atherosclerotic cardiovascular disease risk reduction through hsCRP reduction, and ophthalmology, targeting diabetic macular edema as a proof-of-concept indication.
Beyond NLRP3 inhibition, BioAge is developing novel apelin receptor APJ agonists for obesity treatment, including both oral and parenteral formulations. Preclinical data suggest APJ agonism can substantially enhance weight loss and restore healthy body composition when combined with existing obesity therapeutics. The company has established strategic collaborations with Eli Lilly and Company for earlier-stage platform-derived programs and maintains an ongoing target discovery collaboration with Novartis Pharma AG.
BioAge's intellectual property portfolio includes composition of matter claims and claims covering the novel NLRP3 binding site, with patent protection extending through 2045 prior to patent term restoration. The company's leadership team comprises experienced executives with extensive backgrounds in aging biology, drug development, and biopharmaceutical operations. BioAge operates as a smaller reporting company and is classified as a non-accelerated filer. More information is available at www.bioagelabs.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- EMERYVILLE, CA
- Fiscal year end
- December
- CIK
- 1709941
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BioAge Labs, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BioAge Labs, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BioAge Labs, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BioAge Labs, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BioAge Labs, Inc.'s last four quarterly filings that the numbers alone won't show?”